APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Clinical studies are expected to start in Q2 2023.
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
To create leading company developing medicines targeting metalloenzymes
Subscribe To Our Newsletter & Stay Updated
